Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Operating income | -$4.35M | -$7.82M |
| Net income | -$30.4M | -$8.98M |
| EPS (diluted) | -$0.89 | -$0.20 |
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Operating cash flow | -$2.57M | -$3.94M |
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Cash & equivalents | $4.62M | $5.14M |
| Total assets | $5.00M | $5.17M |
| Total liabilities | $289K | $605K |
| Shareholders' equity | $4.71M | $4.57M |
| Retained earnings | -$90.7M | -$99.6M |
| Shares (wtd avg diluted) | 34.2M | 45.4M |
Every figure is extracted from Polaryx Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.